Latest Lapatinib Stories
MM-111 in pre-clinical combinations with lapatinib and endocrine therapies MM-302 in pre-clinical studies explaining its mechanism of action Cambridge, Mass. (Vocus/PRWEB) April 01, 2011 Merrimack Pharmaceuticals, Inc.
Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers.
For women with aggressive early-stage breast cancer (HER2-positive disease), trastuzumab (Herceptin) given for one year after chemotherapy proved to put the women at significantly less risk of the cancer returning.
SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ -- The U.S.
BURLINGTON, Mass., Oct.
Inflammatory breast cancer (IBC), an aggressive and rare malignancy, is often initially misdiagnosed as an infection or rash.
NUTLEY, N.J., July 26 /PRNewswire/ -- Roche announced today that Karen Lackey has been named Vice President and Head of Medicinal Chemistry, effective immediately.
WALTHAM, Mass., June 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rapid uptake and market penetration of key targeted agents, beginning with Roche/Genentech/Chugai's Herceptin, will drive the gastric cancer drug market to more than double, from $700 million in 2009 to nearly $1.5 billion in 2019. The Pharmacor 2010 findings from the topic entitled Gastric Cancer reveal that the robust...
SAN DIEGO, May 26 /PRNewswire/ -- In a recent study presented at the American Association of Cancer Research Annual Meeting in Washington, DC, researchers at the University of Texas MD Anderson Cancer Center showed that Positron Emission Mammography (PEM) helps evaluate response to neoadjuvant chemotherapy. PEM scanners are high-resolution breast PET systems that can show the location as well as the metabolic phase of a lesion.
WALTHAM, Mass., Feb.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.